Loading…
CytoMed Therapeutics Limited is projected to rise to $1.03 by 2027, a 0% move from its current price of $1.03. GDTC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.9945 | $1.03 | $1.07 | +0.02% |
| Jul 14 | $0.9803 | $1.03 | $1.08 | +0.05% |
| Jul 15 | $0.9696 | $1.03 | $1.10 | +0.07% |
| Jul 16 | $0.9607 | $1.03 | $1.11 | +0.10% |
| Jul 17 | $0.953 | $1.03 | $1.12 | +0.12% |
| Jul 18 | $0.9461 | $1.03 | $1.12 | +0.14% |
| Jul 19 | $0.9398 | $1.03 | $1.13 | +0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.9398 | $1.03 | $1.13 | +0.17% |
| Week 2 | $0.9056 | $1.03 | $1.18 | +0.34% |
| Week 3 | $0.8806 | $1.04 | $1.22 | +0.51% |
| Week 4 | $0.8603 | $1.04 | $1.25 | +0.68% |
| Week 5 | $0.843 | $1.04 | $1.28 | +0.85% |
| Week 6 | $0.8278 | $1.04 | $1.31 | +1.02% |
| Week 7 | $0.8141 | $1.04 | $1.33 | +1.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
CytoMed Therapeutics Limited is a clinical stage biopharmaceutical company focused on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials to improve anti-cancer cytotoxicity.
The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has a research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and a Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT.
CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
CytoMed Therapeutics Limited (GDTC) is a healthcare company focused on developing cell-based immunotherapies for cancer and degenerative diseases. The current price is $1.01 and the market cap is $11.95M, with a rank of 5095 among listed assets.
The stock trades with a bearish near-term flavor reflected by technicals, and is currently trading around the listed moving averages. The 50-day simple moving average is $1.05 and the 200-day simple moving average is $1.42.
In the near term, the stock sits in a defined price range and shows a 30-day range of $0.7446 to $1.37, with a support level at $0.755 and a resistance at $1.32. Annualized volatility is high at 90%.
Overall, near-term conditions are modestly negative, while longer-term forecast data show potential upside over the coming years.
A major floor 29.8% below — a decisive break under it would weaken the trend.
The nearest floor, 5.8% below — buyers have tended to step in here.
The nearest ceiling, 25.2% above — a clean break opens room to run.
A major ceiling 37.5% above — clearing it would confirm fresh momentum.
Key GDTC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GDTC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.984 | Buy | $0.9959 | Buy |
| MA 10 | $0.9935 | Buy | $1.00 | Buy |
| MA 20 | $1.03 | Sell | $1.02 | Buy |
| MA 50 | $1.05 | Sell | $1.05 | Sell |
| MA 100 | $1.04 | Sell | $1.11 | Sell |
| MA 200 | $1.36 | Sell | $1.31 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.42 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | -2.39 | Neutral |
| Williams %R (14) | -45.45 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | 1.98 | Buy |
| Bollinger %B (20,2) | 0.49 | Neutral |
| Stochastic %K (14) | 54.55 | Neutral |
| TRIX (15) | -0.34 | Sell |
| Awesome (5,34) | -0.10 | Sell |
| Ultimate (7,14,28) | 46.36 | Neutral |
| Momentum (10) | 0.04 | Buy |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 0.98 | Buy |
| ADX (14) | 12.86 | Neutral |
| ATR (14) | 0.03 | Info |
The 30-day technical picture shows bearish sentiment with RSI(14) at 40. The price has stayed around the SMA50 of $1.05, indicating tentative near-term pressure relative to the $1.01 current price.
The stock trades within a 30-day range of $0.7446 to $1.37 with a defined support at $0.755 and resistance at $1.32. The near-term setup reflects a tendency toward consolidation rather than a clear breakout. Annualized volatility sits at 90%, underscoring the elevated risk in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.723 | $1.03 | $1.41 | 0% | Neutral | |
| $0.798 | $1.03 | $1.42 | 0% | Neutral | |
| $0.8597 | $1.15 | $1.66 | +12% | Neutral | |
| $0.8652 | $1.20 | $1.79 | +16% | Neutral | |
| $0.9785 | $1.39 | $2.14 | +35% | Bullish | |
| $1.23 | $1.79 | $2.84 | +74% | Bullish | |
| $1.19 | $1.78 | $2.88 | +73% | Bullish | |
| $1.10 | $1.68 | $2.78 | +63% | Bullish | |
| $1.14 | $1.77 | $2.98 | +72% | Bullish | |
| $1.15 | $1.83 | $3.14 | +78% | Bullish | |
| $1.52 | $2.66 | $4.91 | +158% | Bullish | |
| $2.86 | $5.95 | $12.19 | +477% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.723 | $1.03 | $1.27 | +0.00% |
| August 2026 | $0.9113 | $1.08 | $1.33 | +5.28% |
| September 2026 | $0.8768 | $1.05 | $1.31 | -2.90% |
| October 2026 | $0.8554 | $1.04 | $1.30 | -1.68% |
| November 2026 | $0.8847 | $1.08 | $1.37 | +4.11% |
| December 2026 | $0.8944 | $1.10 | $1.41 | +1.73% |
Click any year to see its month-by-month GDTC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, GDTC could reach as high as $1.41, with a base case around $1.03 and support toward $0.723 — roughly 0% from $1.03. A consolidation phase looks the most probable path here.
Expect GDTC to range from $0.798 to $1.42 through 2027. The $1.03 average target implies a 0% move from current prices. That is up 0% on the projected 2026 average. Price action looks broadly range-bound.
The GDTC price prediction for 2028 points to an average of $1.15 (low $0.8597, high $1.66) — a potential gain of +12% on today's $1.03. A consolidation phase looks the most probable path here.
In 2029, GDTC is projected to trade between $0.8652 and $1.79, averaging $1.20 — a potential gain of +16% from today's $1.03. That is up +4% on the projected 2028 average. Price action looks broadly range-bound.
CytoMed Therapeutics Limited's 2030 outlook centres on $1.39, within a $0.9785 to $2.14 range. That is up +16% on the projected 2029 average. That marks a +35% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, GDTC could reach as high as $2.84, with a base case around $1.79 and support toward $1.23 — roughly +74% from $1.03. Momentum favours further upside here.
Expect GDTC to range from $1.19 to $2.88 through 2032. The $1.78 average target implies a +73% move from current prices. That is -1% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
The GDTC price prediction for 2033 points to an average of $1.68 (low $1.10, high $2.78) — a potential gain of +63% on today's $1.03. Momentum favours further upside here.
In 2034, GDTC is projected to trade between $1.14 and $2.98, averaging $1.77 — a potential gain of +72% from today's $1.03. That is up +5% on the projected 2033 average. Buyers look set to stay in control over this stretch.
CytoMed Therapeutics Limited's 2035 outlook centres on $1.83, within a $1.15 to $3.14 range. That is up +3% on the projected 2034 average. That marks a +78% change versus current levels. Momentum favours further upside here.
By 2040, GDTC could reach as high as $4.91, with a base case around $2.66 and support toward $1.52 — roughly +158% from $1.03. Buyers look set to stay in control over this stretch.
Expect GDTC to range from $2.86 to $12.19 through 2050. The $5.95 average target implies a +477% move from current prices. That is up +123% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in GDTC today (≈ 970.873786 GDTC) could be worth
$5,774.38
+$4,774.38 (+477%) by 2050 · US Dollar
Based on the average projected GDTC price of $5.95 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GDTCwould be worth at today's price.
$1,000 invested in GDTC on Jul 10, 2025 (≈ 454.545445 GDTC) would be worth
$468.18
-$531.82 (-53.2%) today · 0.47× · US Dollar
Based on a GDTC entry price of $2.2 vs. today's $1.03.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.975 | $1,056.41 | +5.6% |
| 1 month ago | $1.07 | $967.14 | -3.3% |
| 3 months ago | $1 | $1,030 | +3.0% |
| 6 months ago | $1.24 | $830.65 | -16.9% |
| 1 year ago | $2.2 | $468.18 | -53.2% |
| All time (3.2y) ago | $4 | $257.5 | -74.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GDTC forecast.
Our base-case forecast reaches $2.10 around 2040.
Implied market cap at $2.10: $24.85M
The multi-year forecast shows a shift from neutral near term to bullish longer term. In 2026, the avg price is $1.01 with a min of $0.723 and a max of $1.42, and ROI of 0 with neutral sentiment. The following year remains neutral with an avg of $0.9896 and ROI of -2, then moves higher in 2028 to an avg of $1.11 with ROI 10.1 and in 2029 to an avg of $1.11 with ROI 9.5.
By 2030 the avg price is projected to be $1.39 with a 37.3% ROI and a bullish sentiment. The uptrend continues through 2031 at an average of $1.88 (ROI 86.5) and 2032 at $1.73 (ROI 71.2), followed by 2033 at $1.61 (ROI 59), 2034 at $1.76 (ROI 74.3), and 2035 at $1.71 (ROI 69), all with bullish sentiment.
In 2040 the forecast shows a more pronounced upside with an avg of $2.61 and ROI of 158.4, and by 2050 an avg of $5.99 with ROI 493.4. The max prices in these years extend to $5.37 in 2040 and $13.78 in 2050, reflecting substantial growth potential under the projected path.
These are projection-based estimates, not guarantees. Actual results depend on market conditions, clinical progress of the company's programs, regulatory outcomes, and other factors that can influence equity valuation.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $1.39 with a max of $2.30 and a min of $0.9024, yielding a projected ROI of 37.3% with bullish sentiment.
Near term is Neutral in 2026 with an avg of $1.01 and ROI of 0, while the longer term shows bullish potential from 2030 onward. These are estimates, not guarantees, and should be weighed with other factors.
The 2050 forecast lists a max of $13.78 and an avg of $5.99 with a ROI of 493.4% and bullish sentiment, indicating potential upside but not a guarantee.
$0.7446 to $1.37.
Current price is $1.01 and market cap is $11.95M.
CytoMed Therapeutics Limited Community Discussion
0Share your CytoMed Therapeutics Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.